Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 46

Results For "labs"

458 News Found

Laurus receives license to manufacture and market 2DG
News | July 04, 2021

Laurus receives license to manufacture and market 2DG

2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country


Five manufacturers get license to produce Black Fungus drug
News | May 23, 2021

Five manufacturers get license to produce Black Fungus drug

NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers


Dishman Carbogen Amcis announces successful results for treatment for vitamin D deficiency
News | May 21, 2021

Dishman Carbogen Amcis announces successful results for treatment for vitamin D deficiency

Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.


GlaxoSmithKline approves sale of Vemgal plant
News | April 05, 2021

GlaxoSmithKline approves sale of Vemgal plant

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS


Reports on GSK Pharmaceuticals by ICICI Securities
News | April 03, 2021

Reports on GSK Pharmaceuticals by ICICI Securities

GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn


Govt. receives 215 applications for the 36 products under PLI scheme
News | March 13, 2021

Govt. receives 215 applications for the 36 products under PLI scheme

174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.


Industry-academia collaboration key to strengthening pharma R&D
News | March 04, 2021

Industry-academia collaboration key to strengthening pharma R&D

The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .


Laurus Q3 FY21 revenue up 76%; PAT grows 274%
News | January 29, 2021

Laurus Q3 FY21 revenue up 76%; PAT grows 274%

The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.